2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Working Together to Address Women's Health in Research and Drug Development: Summary of the 2017 Women's Health Congress Preconference Symposium

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Historically, women have been underrepresented in clinical research, requiring physicians to extrapolate medical recommendations for women from clinical research done in cohorts consisting predominantly of male participants. While government-funded clinical research has achieved gender parity in phase-3 clinical trials across many biomedical disciplines, improvements are still needed in several facets of women's health research, such as the inclusion of women in early-phase clinical trials, the inclusion of pregnant women and women with physical and intellectual disabilities, the consideration of sex as a biological variable in preclinical research, and the analysis and reporting of sex and gender differences across the full biomedical research continuum. The National Institutes of Health (NIH) Office of Research on Women's Health and the Office of Women's Health of the U.S. Food and Drug Administration (FDA) cosponsored a preconference symposium at the 25th Annual Women's Health Congress, held in Arlington, VA in April, 2017, to highlight gains made and remaining needs regarding the representation of women in clinical research, to introduce innovative procedures and technologies, and to outline revised policy for future studies. Six speakers presented information on a range of subjects related to the representation of women in clinical research and federal initiatives to advance precision medicine. Topics included the following: the return on investment from the NIH-funded Women's Health Initiative; progress in including women in clinical trials for FDA-approved drugs and products; the importance of clinical trials in pregnant women; FDA initiatives to report drug safety during pregnancy; the NIH-funded All of Us Research Program; and efforts to enhance FDA transparency and communications, including the introduction of Drug Trials Snapshots. This article summarizes the major points of the presentations and the discussions that followed.

          Related collections

          Author and article information

          Journal
          J Womens Health (Larchmt)
          J Womens Health (Larchmt)
          jwh
          Journal of Women's Health
          Mary Ann Liebert, Inc., publishers (140 Huguenot Street, 3rd FloorNew Rochelle, NY 10801USA )
          1540-9996
          1931-843X
          01 October 2018
          12 October 2018
          : 27
          : 10
          : 1195-1203
          Affiliations
          [ 1 ]Office of Research on Women's Health, National Institutes of Health , Bethesda, Maryland.
          [ 2 ] Office of Women's Health , U.S. Food and Drug Administration, Silver Spring, Maryland.
          [ 3 ]Department of Psychiatry and Institute for Women's Health, Virginia Commonwealth University , Richmond, Virginia.
          [ 4 ]Office of Extramural Research, National Institutes of Health , Bethesda, Maryland.
          [ 5 ]Pregnancy and Perinatology Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health , Bethesda, Maryland.
          [ 6 ] Center for Drug Evaluation and Research , U.S. Food and Drug Administration, Silver Spring, Maryland.
          [ 7 ]All of Us Research Program, National Institutes of Health , Bethesda, Maryland.
          Author notes
          [*]Address correspondence to: Janine Austin Clayton, MD, Office of Research on Women's Health, National Institutes of Health, 6707 Democracy Blvd., Suite #400, Bethesda, MD 20892 janine.clayton@ 123456nih.gov
          Article
          PMC6425923 PMC6425923 6425923 10.1089/jwh.2018.29019.pcss
          10.1089/jwh.2018.29019.pcss
          6425923
          30325292
          b416b018-88d2-493f-a4c2-811a8d3c3a5f
          Copyright 2018, Mary Ann Liebert, Inc., publishers
          History
          Page count
          References: 86, Pages: 9
          Categories
          Report from the NIH Office of Research on Women's Health

          precision medicine,pregnancy,clinical trial,women,drug development

          Comments

          Comment on this article